keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/27905851/peptide-receptor-radionuclide-therapy-for-sarcoidosis
#1
Constantin Lapa, Götz Ulrich Grigoleit, Heribert Hänscheid, Erdwine Klinker, Pius Jung, Ken Herrmann, Andreas Schirbel, Markus Böck, Andreas K Buck, Theo Pelzer
No abstract text is available yet for this article.
December 1, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27886159/cardiac-monitoring-in-patients-on-trastuzumab-correlation-of-ultrasound-and-radionuclide-ventriculography
#2
Erika Matos, Borut Jug, Barbara Vidergar Kralj, Branko Zakotnik
BACKGROUND: Guidance on cardiac surveillance during adjuvant trastuzumab therapy remains elusive. The recommended methods are 2-dimensional echocardiography (2D-ECHO) and electrocardiography gated equilibrium radionuclide ventriculography (RNV). We assessed the correlation and possible specific merits of these two methods. METHODS: In a prospective cohort study in patients undergoing post-anthracycline adjuvant trastuzumab therapy, clinical assessment, 2D-ECHO and RNV were performed at baseline, 4, 8 and 12 months...
November 25, 2016: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/27885372/treatment-planning-in-prrt-based-on-simulated-pet-data-and-a-pbpk-model-determination-of-accuracy-using-a-pet-noise-model
#3
Deni Hardiansyah, Wei Guo, Ali Asgar Attarwala, Peter Kletting, Felix M Mottaghy, Gerhard Glatting
AIM: To investigate the accuracy of treatment planning in peptide-receptor radionuclide therapy (PRRT) based on simulated PET data (using a PET noise model) and a physiologically based pharmacokinetic (PBPK) model. METHODS: The parameters of a PBPK model were fitted to the biokinetic data of 15 patients. True mathematical phantoms of patients (MPPs) were the PBPK model with the fitted parameters. PET measurements after bolus injection of 150 MBq (68)Ga-DOTATATE were simulated for the true MPPs...
November 25, 2016: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/27882120/lutetium-177-dota-tate-therapy-for-esthesioneuroblastoma-a-case-report
#4
Juliano Guerra Sabongi, Mônica Carboni Pereira Gonçalves, Cira Danielle Casado Alves, João Alves, Cristovam Scapulatempo-Neto, Sonia Marta Moriguchi
Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27875420/molecular-imaging-in-neuroendocrine-tumors-recent-advances-controversies-unresolved-issues-and-roles-in-management
#5
Tetsuhide Ito, Robert T Jensen
PURPOSE OF REVIEW: The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management. RECENT FINDINGS: Molecular imaging of NETs underwent a number of important changes in the last few years, leading to some controversies, unresolved issues, and significant changes in clinical management. The most recent changes are reviewed in this article. Particularly important is the rapid replacement in somatostatin receptor scintigraphy of In-diethylenetriamine penta-acetic acid-single-photon emission computed tomography/computed tomography (CT) by Ga-fluorodopa(F-D)PA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide-PET/CT imaging, which is now approved in many countries including the USA...
November 21, 2016: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/27873240/improved-safety-and-efficacy-of-213-bi-dotatate-targeted-alpha-therapy-of-somatostatin-receptor-expressing-neuroendocrine-tumors-in-mice-pre-treated-with-l-lysine
#6
Ho Sze Chan, Mark W Konijnenberg, Tamara Daniels, Monique Nysus, Mehran Makvandi, Erik de Blois, Wouter A Breeman, Robert W Atcher, Marion de Jong, Jeffrey P Norenberg
BACKGROUND: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with (177)Lu-DOTATATE or (90)Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tubules. Pharmacological protection can reduce renal uptake of radiopeptides, e.g., positively charged amino acids, to saturate in the proximal tubules, thereby enabling higher radioactivity to be safely administered...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27865641/canadian-cardiovascular-society-guidelines-on-perioperative-cardiac-risk-assessment-and-management-for-patients-who-undergo-noncardiac-surgery
#7
Emmanuelle Duceppe, Joel Parlow, Paul MacDonald, Kristin Lyons, Michael McMullen, Sadeesh Srinathan, Michelle Graham, Vikas Tandon, Kim Styles, Amal Bessissow, Daniel I Sessler, Gregory Bryson, P J Devereaux
The Canadian Cardiovascular Society Guidelines Committee and key Canadian opinion leaders believed there was a need for up to date guidelines that used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system of evidence assessment for patients who undergo noncardiac surgery. Strong recommendations included: 1) measuring brain natriuretic peptide (BNP) or N-terminal fragment of proBNP (NT-proBNP) before surgery to enhance perioperative cardiac risk estimation in patients who are 65 years of age or older, are 45-64 years of age with significant cardiovascular disease, or have a Revised Cardiac Risk Index score ≥ 1; 2) against performing preoperative resting echocardiography, coronary computed tomography angiography, exercise or cardiopulmonary exercise testing, or pharmacological stress echocardiography or radionuclide imaging to enhance perioperative cardiac risk estimation; 3) against the initiation or continuation of acetylsalicylic acid for the prevention of perioperative cardiac events, except in patients with a recent coronary artery stent or who will undergo carotid endarterectomy; 4) against α2 agonist or β-blocker initiation within 24 hours before surgery; 5) withholding angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker starting 24 hours before surgery; 6) facilitating smoking cessation before surgery; 7) measuring daily troponin for 48 to 72 hours after surgery in patients with an elevated NT-proBNP/BNP measurement before surgery or if there is no NT-proBNP/BNP measurement before surgery, in those who have a Revised Cardiac Risk Index score ≥1, age 45-64 years with significant cardiovascular disease, or age 65 years or older; and 8) initiating of long-term acetylsalicylic acid and statin therapy in patients who suffer myocardial injury/infarction after surgery...
October 4, 2016: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/27863570/radionuclide-therapies-in-molecular-imaging-and-precision-medicine
#8
REVIEW
A Tuba Kendi, Valeria M Moncayo, Jonathon A Nye, James R Galt, Raghuveer Halkar, David M Schuster
This article reviews recent advances and applications of radionuclide therapy. Individualized precision medicine, new treatments, and the evolving role of radionuclide therapy are discussed.
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27862203/production-quality-control-and-determination-of-human-absorbed-dose-of-no-carrier-added-177-lu-risedronate-for-bone-pain-palliation-therapy
#9
Nafise Salek, Mohsen Mehrabi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mostafa Erfani, Sara Vosoghi, Mohammad Ghannadi Maragheh, Mojtaba Shamsaei
In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) (177) Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy β(-) emitter, (177) Lu (T½  = 6.7 days, Eβmax  = 497 keV), has been considered as a potential agent for development of bone-seeking radiopharmaceuticals. Because the specific activity of the radiolabeled carrier molecules should be high, the NCA radionuclides have an effective role in nuclear medicine...
November 15, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27853048/does-combination-of-cold-and-hot-somatostatin-analogs-prolong-survival-of-patients-with-neuroendocrine-neoplasms
#10
Anna Sowa-Staszczak, Agnieszka Stefanska, Pawel Chrapczynski, Malgorzata Trofimiuk-Müldner, Miroslaw Szura, Alicja Hubalewska-Dydejczyk
A number of detected neuroendocrine neoplasms (NENs) has been on the increase due to our awareness of the NENs risk and the development of different imaging techniques. Therapy of NENs involves surgery, chemotherapy, "cold" somatostatin analogs (SSA), peptide receptor radionuclide therapy (PRRT) and kinase inhibitors in pancreatic NENs. The aim of this study is to assess the efficacy of SSA in combination with "hot" somatostatin analogs, and the survival rate of our patients with advanced NENs. Seventy nine patients with metastatic NEN and positive somatostatin receptor scintigraphy (SRS) were enrolled in the study...
November 17, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27846003/imaging-of-prostate-specific-membrane-antigen-expression-in-metastatic-differentiated-thyroid-cancer-using-68ga-hbed-cc-psma-pet-ct
#11
Susanne Lütje, Benedikt Gomez, Joseph Cohnen, Lale Umutlu, Martin Gotthardt, Thorsten D Poeppel, Andreas Bockisch, Sandra Rosenbaum-Krumme
PURPOSE: The prostate-specific membrane antigen (PSMA) was shown to be overexpressed on the neovasculature of several malignancies. Here, the role of Ga-HBED-CC-PSMA PET/CT for the detection of PSMA expression in patients with metastasized differentiated thyroid cancer (DTC) was evaluated. METHODS: Six patients with iodine-negative and F-FDG-positive metastasized DTC (mean TG, 1616 ng/mL) received 71-93 MBq of the Ga-labeled PSMA ligand and underwent PET/CT at 62 ± 7 minutes p...
November 11, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27837538/techniques-for-loading-technetium-99m-and-rhenium-186-188-radionuclides-into-preformed-liposomes-for-diagnostic-imaging-and-radionuclide-therapy
#12
Beth Goins, Ande Bao, William T Phillips
Liposomes can serve as carriers of radionuclides for diagnostic imaging and therapeutic applications. Herein, procedures are outlined for radiolabeling liposomes with the gamma-emitting radionuclide, technetium-99m ((99m)Tc), for noninvasive detection of disease and for monitoring the pharmacokinetics and biodistribution of liposomal drugs, and/or with therapeutic beta-emitting radionuclides, rhenium-186/188 ((186/188)Re), for radionuclide therapy. These efficient and practical liposome radiolabeling methods use a post-labeling mechanism to load (99m)Tc or (186/188)Re into preformed liposomes prepared in advance of the labeling procedure...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27831759/triple-therapy-of-her2-cancer-using-radiolabeled-multifunctional-iron-oxide-nanoparticles-and-alternating-magnetic-field
#13
Hamidreza Zolata, Hossein Afarideh, Fereydoun Abbasi Davani
By using radio-labeled multifunctional superparamagnetic iron oxide nanoparticles (SPIONs) and an alternating magnetic field (AMF), we carried out targeted hyperthermia, drug delivery, radio-immunotherapy (RIT), and controlled chemotherapy of cancer tumors. We synthesized and characterized Indium-111-labeled, Trastuzumab and Doxorubicin (DOX)-conjugated APTES-PEG-coated SPIONs in our previous work. Then, we evaluated their capability in SPECT/MRI (single photon emission computed tomography/magnetic resonance imaging) dual modal molecular imaging, targeting, and controlled release...
November 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27825432/psma-pet-and-radionuclide-therapy-in-prostate-cancer
#14
REVIEW
Kirsten Bouchelouche, Baris Turkbey, Peter L Choyke
Prostate cancer (PCa) is the most common malignancy in men and a major cause of cancer death. Accurate imaging plays an important role in diagnosis, staging, restaging, detection of biochemical recurrence, and for therapy of patients with PCa. Because no effective treatment is available for advanced PCa, there is an urgent need to develop new and more effective therapeutic strategies. To optimize treatment outcome, especially in high-risk patients with PCa, therapy for PCa is moving rapidly toward personalization...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27821344/nuclear-data-for-production-and-medical-application-of-radionuclides-present-status-and-future-needs
#15
REVIEW
Syed M Qaim
INTRODUCTION: The significance of nuclear data in the choice and medical application of a radionuclide is considered: the decay data determine its suitability for organ imaging or internal therapy and the reaction cross section data allow optimisation of its production route. A brief discussion of reaction cross sections and yields is given. STANDARD RADIONUCLIDES: The standard SPECT, PET and therapeutic radionuclides are enumerated and their decay and production data are considered...
September 2, 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/27816974/troponin-i-and-d-dimer-for-discriminating-acute-pulmonary-thromboembolism-from-myocardial-infarction
#16
Soo Jin Kim, Moo Hyun Kim, Kwang Min Lee, Tae Hyung Kim, Sun Yong Choi, Min Kook Son, Ji Woen Park, Victor L Serebruany
BACKGROUND: Acute pulmonary thromboembolism (APTE) is a life-threatening condition, often manifesting with chest pain, dyspnea, and increased cardiac biomarkers including cardiac troponin I (CTI) and D-dimer. Therefore, APTE is often misdiagnosed with classical non-ST elevation myocardial infarction (NSTEMI), resulting in unnecessary coronary interventions and a delay of therapy. OBJECTIVES: Our aim was to distinguish APTE from NSTEMI based on CTI and D-dimer levels...
November 5, 2016: Cardiology
https://www.readbyqxmd.com/read/27813061/development-of-lu-177-trastuzumab-for-radioimmunotherapy-of-her2-expressing-breast-cancer-and-its-feasibility-assessment-in-breast-cancer-patients
#17
Priya Bhusari, Rakhee Vatsa, Gurpreet Singh, Madan Parmar, Amanjit Bal, Devinder K Dhawan, Bhagwant R Mittal, Jaya Shukla
HER2/neu is over expressed in 20-25% of breast cancers. HER2 breast cancers are aggressive and are associated with poor prognosis. The aim of this study was to develop the clinical grade Lu-177-trastuzumab and its preliminary evaluation for specific tumor targeting in HER2 positive breast cancer patients. Trastuzumab was conjugated to bifunctional chelator, DOTA, and characterized for integrity and the number of molecules conjugated. Radiolabeling of DOTA-conjugated trastuzumab was optimized using Lu-177. Quality control parameters including radiochemical purity, stability, sterility, pyrogenicity and immunoreactivity were assessed...
November 3, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27811124/molecular-imaging-of-gastroenteropancreatic-neuroendocrine-tumors-current-status-and-future-directions
#18
Christophe M Deroose, Elif Hindié, Electron Kebebew, Bernard Goichot, Karel Pacak, David Taïeb, Alessio Imperiale
Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine has earned a major role in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs are diagnosed based on symptoms, hormonal syndrome, or fortuitously. Based on functional tumor characteristics, radionuclide imaging allows for more accurate staging and treatment selection. Tumor grade helps determine which tracer(s) should be selected. In the past, (111)In-pentetreotide has been successful in well-differentiated (G1/G2) tumors...
November 3, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27806616/development-of-a-transmission-alpha-particle-dosimetry-technique-using-a549-cells-and-a-ra-223-source-for-targeted-alpha-therapy
#19
R Al Darwish, A H Staudacher, Y Li, M P Brown, E Bezak
PURPOSE: In targeted radionuclide therapy, regional tumors are targeted with radionuclides delivering therapeutic radiation doses. Targeted alpha therapy (TAT) is of particular interest due to its ability to deliver alpha particles of high linear energy transfer within the confines of the tumor. However, there is a lack of data related to alpha particle distribution in TAT. These data are required to more accurately estimate the absorbed dose on a cellular level. As a result, there is a need for a dosimeter that can estimate, or better yet determine the absorbed dose deposited by alpha particles in cells...
November 2016: Medical Physics
https://www.readbyqxmd.com/read/27802058/engineered-recognition-of-tetravalent-zirconium-and-thorium-by-chelator-protein-systems-toward-flexible-radiotherapy-and-imaging-platforms
#20
Ilya Captain, Gauthier J-P Deblonde, Peter B Rupert, Dahlia D An, Marie-Claire Illy, Emeline Rostan, Corie Y Ralston, Roland K Strong, Rebecca J Abergel
Targeted α therapy holds tremendous potential as a cancer treatment: it offers the possibility of delivering a highly cytotoxic dose to targeted cells while minimizing damage to surrounding healthy tissue. The metallic α-generating radioisotopes (225)Ac and (227)Th are promising radionuclides for therapeutic use, provided adequate chelation and targeting. Here we demonstrate a new chelating platform composed of a multidentate high-affinity oxygen-donating ligand 3,4,3-LI(CAM) bound to the mammalian protein siderocalin...
November 1, 2016: Inorganic Chemistry
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"